Nektar Therapeutics (LTS:0UNL) Research & Development: $122.53 Mil (TTM As of Mar. 2026)


LTS:0UNL Nektar Therapeutics LTS:0UNL
49 GF Score
Price $61.67
GF Value $5.81
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nektar Therapeutics Research & Development?

Nektar Therapeutics LTS:0UNL -0.40% 49 Research & Development is $122.53 Mil as of Mar. 2026. GuruFocus rates LTS:0UNL with a GF Score™ of 49/100 and a GF Value™ of $5.81 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Nektar Therapeutics's Research & Development for the three months ended in Mar. 2026 was $35.68 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $122.53 Mil.

Nektar Therapeutics  (LTS:0UNL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Nektar Therapeutics Research & Development Related Terms

Nektar Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Nektar Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics Research & Development Chart

Nektar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 400.27 218.32 114.16 120.91 117.33

Nektar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.48 29.89 27.25 29.71 35.68
LTS:0UNL
49GF Score
Nektar Therapeutics LTS:0UNL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nektar Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $122.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $122.53 Mil mean?
Nektar Therapeutics (LTS:0UNL) has a Research & Development of $122.53 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Nektar Therapeutics and its competitors.
Is Nektar Therapeutics' Research & Development too high?
Nektar Therapeutics' current Research & Development is $122.53 Mil. Overall, Nektar Therapeutics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' Research & Development compare to PHVS and KOD?
Nektar Therapeutics' Research & Development of $122.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Nektar Therapeutics and its competitors. Nektar Therapeutics's current Research & Development is $122.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nektar Therapeutics (LTS:0UNL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.81, compared to a current price of $61.67 — trading 961.4% above its estimated fair value. The current Research & Development is $122.53 Mil. Nektar Therapeutics' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Nektar Therapeutics (LTS:0UNL), the current Research & Development is $122.53 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nektar Therapeutics (LTS:0UNL) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of $61.67 is trading 961.4% above its estimated GF Value™ of $5.81. GuruFocus considers Nektar Therapeutics to be Significantly Overvalued.

Key valuation signals for LTS:0UNL:

  • Research & Development: $122.53 Mil
  • GF Value™: $5.81 vs. price of $61.67 (961.4% above fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the LTS:0UNL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nektar Therapeutics Business Description

Other Exchanges NKTR:USAITH0:Germany
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
49GF Score

Get the complete analysis for LTS:0UNL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$61.67
Price
$5.81
GF Value